Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Submitted by
admin
on August 29, 2018 - 12:42pm
Source:
CP Wire
News Tags:
TrovaGene
Onvansertib
AML
mCRPC
non-Hodgkin lymphoma
triple negative breast cancer
Headline:
Trovagene Receives Orphan Drug Designation for Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
snippet:
Onvansertib also has orphan status in the US
Onvansertib has the potential to improve clinical efficacy in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC), Non-Hodgkin Lymphoma (NHL), Triple Negative Breast Cancer (TNBC), as well as other types of cancer.
Do Not Allow Advertisers to Use My Personal information
